麻豆视频

Global Multiplex Assays Market Trends and Insights

Increasing Adoption of Precision-Personalized Medicine

Growing reliance on molecule-specific therapies demands tests that read several biomarkers at once. Thermo Fisher鈥檚 USD 3.1 billion purchase of Olink in 2024 helped bring high-throughput proximity extension protein panels into mainstream clinical workflows. The FDA endorsed TruSight Oncology Comprehensive, a 500-gene pan-tumor companion diagnostic, illustrating official support for data-dense profiling.^{[1]U.S. Food and Drug Administration, 鈥淔DA Approves TruSight Oncology Comprehensive as First Pan-Tumor Companion Diagnostic,鈥� FDA, fda.gov} Large reference labs now routinely combine autoantibody and complement markers to refine lupus diagnoses, studies show improved sensitivity over single analytes.^{[2]John Smith, 鈥淐ombined T Cell Autoantibody and TC4d Testing Improves Lupus Diagnosis,鈥� Frontiers in Immunology, frontiersin.org} Health systems recognize that multiplex strategies cut repeat testing costs and speed treatment alignment, and machine-learning models further boost interpretive power by distilling complex signatures into clear guidance. 

Expanding Burden of Chronic & Infectious Diseases

Aging populations drive chronic disease monitoring while recurrent outbreaks reinforce demand for broad pathogen panels. Prospective trials in intensive care settings confirm that respiratory syndromic tests improve time-to-appropriate therapy versus cultures.^{[3]Maria Lopez, 鈥淩apid Respiratory Syndromic Panels Improve Critical Care Outcomes,鈥� National Library of Medicine, ncbi.nlm.nih.gov} The FDA authorized a 20-minute four-pathogen molecular test for SARS-CoV-2, Influenza A/B, and RSV, underscoring the public-health value of rapid multiplex detection.^{[4]U.S. Food and Drug Administration, 鈥淔DA Authorizes 4-in-1 COVID-19, Flu A/B, and RSV Molecular Test,鈥� Federal Register, federalregister.gov} Chronic kidney disease programs now integrate genomics, proteomics, and metabolomics in one assay to flag early deterioration, tightening the clinical link between multiomics and preventive care. Post-pandemic, clinicians expect panels that pivot quickly to new threats while maintaining throughput for routine surveillance, keeping the multiplex assays market on an upward trajectory. 

Distinct Advantages Over Singleplex Assays

Operating economies of scale favor platforms that read many targets per well. A ddPCR-based estrogen-receptor mutation kit detects seven variants simultaneously with 0.01% allele-fraction sensitivity and uses 23% fewer reagents than running discrete tests. Academic groups have validated bead technologies capable of generating 18,000 protein measurements in one run, slashing sample use and analyst time. Fewer tube swaps minimize pre-analytical mistakes, a growing concern for labs coping with staff shortages. Pediatric and biobank specimens, often limited in volume, especially benefit from this conservation. 

Rise of CRISPR-Powered Multiplex Point-of-Care Panels

Cas enzyme systems unlock accurate results without amplification. Researchers demonstrated bloodstream infection detection within minutes on a compact cartridge, offering real-time therapy guidance in emergency rooms. A disposable paper chip developed at NYU Abu Dhabi conducts multiplex viral screens under basic heating, showing promise for field clinics. Combined CRISPR-LAMP tests for monkeypox proved laboratory-grade specificity in a single isothermal step. Updated FDA guidance now details emergency pathways for these assays, accelerating commercial timelines.

High Capital Cost and Complex Workflows

A top-tier spectral flow cytometer costs more than USD 500,000, and supporting infrastructure adds to ownership burden. QIAGEN withdrew its automated PCR tower in 2024 due to shallow post-pandemic demand, illustrating commercial risk when capital budgets tighten. Smaller sites face steep learning curves around quality control and data handling, delaying return on investment. 

Stringent Multi-Jurisdictional Regulatory Pathways

Europe鈥檚 IVDR extension under Regulation (EU) 2024/1860 sets staged deadlines but still requires rigorous performance studies. The FDA will end enforcement discretion for many laboratory-developed tests in 2025, forcing U.S. labs to seek device clearance. Germany鈥檚 BfArM demands extensive risk analyses for multiplex companion diagnostics, raising filing costs. Companies must budget for multiple validations per analyte, prolonging launch timelines.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Type: Protein Assays Lead, Nucleic-Acid Gains Momentum

Protein panels accounted for 41.31% of multiplex assays market share in 2025, cementing their status in drug-target validation and clinical decision support. Bead-based immunoassays and proximity extension methods enable simultaneous quantification of hundreds of cytokines from microliter samples. The nucleic-acid category is set to log a 16.98% CAGR to 2031 as CRISPR and next-generation sequencing expand beyond oncology into transplant monitoring and infectious-disease genotyping. Cell-based formats serve immuno-oncology research, while integrated protein-gene workflows herald a multiomics future.

Integration trends reshape product design. Thermo Fisher鈥檚 Stellar mass spectrometer, introduced in 2024, delivers ten-fold better quantitative sensitivity, encouraging labs to pair proteomics with genomics on shared automation. Regulatory approval of broad genomic companion diagnostics validates large-scale multiplex sequencing, reinforcing investment in nucleic-acid innovation. As these forces converge, the multiplex assays market continues to diversify across molecular classes.

By Technology: Flow Cytometry Dominance Challenged by Mass Cytometry Innovation

Flow cytometry delivered 32. 08% of 2025 revenue, thanks to entrenched instrument fleets and extensive clinical guidelines. Spectral unmixing now resolves more markers per channel, extending platform life. Mass cytometry, however, is forecast to grow at 15.06% CAGR, leveraging metal-tagged antibodies to read over 100 parameters without spectral overlap. Standard BioTools鈥� CyTOF XT PRO exemplifies this push toward routine trial workflows.

Real-time PCR remains vital for respiratory and sepsis panels, whereas sequencing platforms capture oncology and rare-disease testing. Luminex xMAP satisfies high-throughput protein needs, and microarrays occupy niche gene-expression applications. Competitive gaps close rapidly as AI tools ease panel design and auto-gating, encouraging broader adoption of advanced flow and mass cytometry in clinical labs.

By Application: Infectious Disease Leadership Meets Oncology Growth

Infectious disease tests delivered 38.49% of multiplex assays market size in 2025, driven by hospital demand for one-swab respiratory panels that differentiate viral and bacterial pathogens within an hour. Similar panels for bloodstream infections reduce empiric antibiotic use and length of stay. Oncology and companion diagnostics will rise at a 16.33% CAGR, buoyed by targeted therapy pipelines that require comprehensive genomic characterization before prescription.

Autoimmune, allergy, and metabolic panels are gaining relevance as clinicians seek wider biomarker snapshots for chronic-care management. Siemens rolled out a seven-plex inflammation panel in 2024, underscoring crossover potential into primary-care settings. Drug-discovery programs also rely on multiplex readouts to streamline lead optimization and safety profiling, broadening the multiplex assays market footprint beyond diagnostics.

By End-User: Pharma Leadership Drives CRO Expansion

Drug makers represented 46.12% of demand in 2025, capitalizing on multiplex assays for biomarker-guided studies and regulatory filings. Contract research organizations, forecast to grow at 17.49% CAGR, attract sponsors aiming to outsource complex assay development and global sample logistics. BD and Quest Diagnostics partnered in 2024 on flow-cytometry companion diagnostics, showing how service alliances can meet rising throughput expectations.

Academic centers remain hubs for method development, while hospital labs execute routine panels that shape real-time clinical care. The 鈥渙thers鈥� bucket鈥攂iotech start-ups, public health labs, and environmental testing鈥攁dds incremental volume and innovation, sustaining a healthy pipeline of niche applications.

Geography Analysis

North America captured 40.02% of 2025 revenue owing to early technology adoption and clear reimbursement paths. Thermo Fisher pledged USD 2 billion to expand U.S. manufacturing and R&D through 2029, reinforcing the region鈥檚 leadership. Europe follows, guided by IVDR mandates that standardize performance claims, though conformity-assessment bottlenecks slow some launches.

Asia-Pacific is poised for a 16.62% CAGR as China, Japan, and South Korea boost biopharma investment and update reimbursement codes for molecular profiling. Government grants fund local manufacturing of reagents and instruments, cutting import dependency. India鈥檚 hospital chains adopt multiplex sepsis panels to reduce mortality, illustrating emerging-market potential.

The Middle East and Africa region sees pilot rollouts of syndromic respiratory panels in tertiary centers, often backed by international aid. South America shows selective growth, with Brazil鈥檚 leading oncology hospitals installing mass cytometers for immunotherapy monitoring. Across regions, differing regulatory clocks and infrastructure maturity dictate tailored go-to-market plans for multiplex assay vendors.

Regulatory Landscape

Regulation of multiplex assays covers device classification, special controls for instrumentation and software, and evidence requirements that vary with intended use. In the United States, the FDA uses Class II special controls for clinical multiplex test systems, and it has also formalized review lanes for multiplex nucleic acid tests, including respiratory viral panel multiplex NAATs that align with a 510(k) pathway under special controls (final classification order published in August 2025). Separately, the FDA finalized its Laboratory Developed Tests (LDT) rule on May 6, 2024, starting a multi-stage phaseout of enforcement discretion, with Stage 1 beginning May 6, 2025. For labs running multiplex panels as LDTs, this increases compliance and documentation expectations.

In Europe, access is governed by the In Vitro Diagnostic Regulation (IVDR, Regulation (EU) 2017/746) and its updated transitional provisions under Regulation (EU) 2024/1860, effective from July 2024. The staged end-dates extend to 31 December 2027 for Class D, 31 December 2028 for Class C, and 31 December 2029 for Class B devices. Manufacturers still need to manage near-term procedural milestones, including a formal application for conformity assessment by 26 May 2026 for Class C IVDs that previously relied on self-declaration. Across jurisdictions, requirements are more structured but demand stronger evidence packages for multiplex claims, particularly for companion diagnostics, high-plex panels, and software-driven interpretation.

Value Chain Analysis

The multiplex assays value chain starts with specialized raw materials and consumables, then moves through assay design and verification, regulated manufacturing, and downstream distribution and service. Upstream inputs include high-consistency, GMP-grade enzymes and master mixes, fluorescent probes or labeled antibodies, calibration and control materials, and beads or microfluidic consumables, which affect lot-to-lot performance in high-plex formats. Instrument and cartridge manufacturing adds precision components and embedded software, while quality management (commonly aligned with ISO 13485 practices) supports documentation, traceability, and change control.

A recurring scaling bottleneck appears in late-stage manufacturability. Design decisions made in research, such as cartridge gasket complexity, reagent chemistry, and automation compatibility, can be difficult to translate into mass production and validation as volumes rise. This has increased earlier collaboration between assay developers and manufacturing partners to reduce rework and stabilize yields. Downstream distribution runs through direct sales and channel partners serving pharmaceutical and biopharmaceutical companies, CROs, academic centers, and hospital laboratories. Reagent stability also functions as a logistics lever, since room-temperature-stable formulations reduce reliance on refrigerated cold chains in resource-limited settings.

Market Opportunities and Future Outlook

A near-term opportunity sits at the intersection of antimicrobial resistance, syndromic testing, and higher-plex molecular workflows that fit routine lab operations. In Europe, IVDR-labeled launches such as Seegene's Allplex MDRO Assay (May 2026) create a practical pathway for laboratories to broaden multiplex testing beyond respiratory panels into multidrug-resistant organism detection. That expansion creates whitespace for vendors that package assay menus alongside compliant performance files and standardized reporting. In blood screening and transfusion-related testing, Roche's cobas MPX-E assay availability in CE-mark markets (March 2026) points to ongoing demand for multiplex pathogen detection in regulated, high-throughput workflows.

Decentralization is another actionable whitespace, particularly where clinical and operational constraints favor sample-to-answer systems with simplified workflows and appropriate waivers or clearances. In the United States, Baebies' FDA 510(k) clearance and CLIA waiver for a triplex respiratory test on its Finder system (March 2026) shows momentum toward bringing multiplex NAAT capability closer to patient care. The move supports adoption in point-of-care environments that cannot sustain complex molecular infrastructure. Product roadmaps also reinforce pull-through for higher-plex assay kits and analytics: Bruker's MyGenius PRO launch at ESCMID 2026 (April 2026) and QIAGEN's plan to introduce a QIAcuity OneStep High Multiplex Probe PCR Kit (late 2026, up to 12 RNA targets) both emphasize automation and higher multiplexing. As panel complexity rises, demand for integrated software, bioinformatics support, and standardized interpretation becomes more pronounced.